ERX 358
Alternative Names: ERX-358Latest Information Update: 09 Jun 2022
At a glance
- Originator EtiraRx
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Pancreatic cancer
Most Recent Events
- 09 Jun 2022 ERX 358 is available for licensing as of 09 Jun 2022. https://www.etirarx.com/mission-vision/
- 09 Jun 2022 Early research in Pancreatic cancer in USA (unspecified route) before June 2022 (EtiraRx pipeline, June 2022)